About Stephen Dale
Stephen Dale is a chief medical officer at Syncromune.
Stephen Dale reports to the SEC as an officer of 1 public company: Kura Oncology (KURA).
Stephen Dale first appears on SEC filings in 2020.
Experience
This experience comes from Stephen Dale's profile and from SEC filings. For roles taken from filings, the years are when the filings name Stephen Dale in the role, so the role may have started earlier or lasted longer.
SY
Syncromune® Current
Chief Medical Officer
2026 – Present
Syncromune, Inc.
Chief Medical Officer
2026 · Fort Lauderdale, FL
Develops investigational immune therapies for people with metastatic solid tumors.
KI
Kura Oncology, Inc.
Chief Medical Officer and Head of R&D
2020 – 2025 · Public company (KURA)
KS
Kyowa Kirin, Inc.- U.S.
Senior Vice President and Global Head of Medical Science Biologics - R&D
2015 – 2020
AS
AstraZeneca
Vice President & Global Head of Clinical Oncology Precision Medicine,
2006 – 2015
BH
BHI
Development Physician: Clinical Trialist R&D
2003 – 2006
Key Colleagues at Startups
The people Stephen Dale works with at each company, as listed on that company's latest Form D.
Syncromune, Inc. · Form D/A, May 11, 2026
JG
Joseph Gerardi
Executive officer
Jeffrey Cleland
Director
Douglas Watson
Lead Independent Director
JM
Joseph Maroon
Director
NS
Norman Schwartz
Director
Charles Link
Executive Chairman & Chief Innovation Officer
Eamonn Hobbs
President & Chief Executive Officer, director
Kerri-Ann Millar
Chief Financial Officer
Agustin Gago
Chief Operating Officer